Prelude Therapeutics annual total liabilities
2019
2020
2021
2022
2023
2024
2025
Prelude Therapeutics Total Liabilities Growth & History (PRLD)
Prelude Therapeutics's total liabilities was $72.7M for fiscal 2025.
View full Prelude Therapeutics company overviewPrelude Therapeutics annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $72.7M | $28.6M | +64.97% |
| 2024 | 2024-12-31 | $44.1M | $3.5M | +8.58% |
| 2023 | 2023-12-31 | $40.6M | $15.5M | +61.89% |
| 2022 | 2022-12-31 | $25.1M | $5.9M | +30.53% |
| 2021 | 2021-12-31 | $19.2M | $7.8M | +68.33% |
| 2020 | 2020-12-31 | $11.4M | $6.6M | +135.68% |
| 2019 | 2019-12-31 | $4.8M | — | — |
Prelude Therapeutics quarterly total liabilities
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $55.6M | $16.6M | +42.35% |
| Q1 2026 | 2026-03-31 | $59.5M | $21.4M | +56.13% |
| Q4 2025 | 2025-12-31 | $72.7M | $28.6M | +64.97% |
| Q3 2025 | 2025-09-30 | $36.2M | −$4.6M | −11.20% |
| Q2 2025 | 2025-06-30 | $39.1M | −$2.9M | −6.99% |
| Q1 2025 | 2025-03-31 | $38.1M | $1.7M | +4.70% |
| Q4 2024 | 2024-12-31 | $44.1M | $3.5M | +8.58% |
| Q3 2024 | 2024-09-30 | $40.8M | $20.5M | +101.39% |
| Q2 2024 | 2024-06-30 | $42.0M | $23.5M | +126.48% |
| Q1 2024 | 2024-03-31 | $36.4M | $13.3M | +57.98% |
| Q4 2023 | 2023-12-31 | $40.6M | $15.5M | +61.89% |
| Q3 2023 | 2023-09-30 | $20.3M | −$4.7M | −18.72% |
| Q2 2023 | 2023-06-30 | $18.6M | $340,000 | +1.87% |
| Q1 2023 | 2023-03-31 | $23.0M | $4.2M | +22.08% |
| Q4 2022 | 2022-12-31 | $25.1M | $5.9M | +30.53% |
| Q3 2022 | 2022-09-30 | $24.9M | $4.9M | +24.76% |
| Q2 2022 | 2022-06-30 | $18.2M | $3.0M | +19.65% |
| Q1 2022 | 2022-03-31 | $18.9M | $5.6M | +42.18% |
| Q4 2021 | 2021-12-31 | $19.2M | $7.8M | +68.33% |
| Q3 2021 | 2021-09-30 | $20.0M | $8.6M | +75.62% |
| Q2 2021 | 2021-06-30 | $15.2M | — | — |
| Q1 2021 | 2021-03-31 | $13.3M | — | — |
| Q4 2020 | 2020-12-31 | $11.4M | $6.6M | +135.68% |
| Q3 2020 | 2020-09-30 | $11.4M | — | — |
| Q4 2019 | 2019-12-31 | $4.8M | — | — |
Prelude Therapeutics total liabilities trends
Over the last five fiscal years, Prelude Therapeutics's total liabilities increased from $11.4M to $72.7M, a change of $61.3M. The latest reported quarter, Q2 2026, shows $55.6M.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prelude Therapeutics source filings ↗Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...